These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19886114)

  • 1. Modern methods of pharmacovigilance: detecting adverse effects of drugs.
    Norén GN; Edwards IR
    Clin Med (Lond); 2009 Oct; 9(5):486-9. PubMed ID: 19886114
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring and managing adverse drug reactions.
    Fincham JE
    Am Pharm; 1992 Feb; NS32(2):74-81. PubMed ID: 1546634
    [No Abstract]   [Full Text] [Related]  

  • 3. Wonder vigilance.
    Edwards IR
    Drug Saf; 2010 Feb; 33(2):83-6. PubMed ID: 20088622
    [No Abstract]   [Full Text] [Related]  

  • 4. EIDOS: a mechanistic classification of adverse drug effects.
    Ferner RE; Aronson JK
    Drug Saf; 2010 Jan; 33(1):15-23. PubMed ID: 20000863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicine Safety Monitoring in Pediatric Population in India.
    Kaur I; Kalaiselvan V; Singh GN
    Indian J Pediatr; 2016 May; 83(5):479-80. PubMed ID: 26634262
    [No Abstract]   [Full Text] [Related]  

  • 7. Who cares about pharmacovigilance?
    Edwards IR
    Eur J Clin Pharmacol; 1997; 53(2):83-8. PubMed ID: 9403276
    [No Abstract]   [Full Text] [Related]  

  • 8. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on: "Pharmacovigilance in the Middle East".
    Al-Worafi YM
    Drug Saf; 2014 Aug; 37(8):651-2. PubMed ID: 24985531
    [No Abstract]   [Full Text] [Related]  

  • 10. Identifying signals of interest when screening for drug-outcome associations in health care data.
    Pottegård A; Hallas J; Wang SV; Gagne JJ
    Br J Clin Pharmacol; 2018 Sep; 84(9):1865-1867. PubMed ID: 29862551
    [No Abstract]   [Full Text] [Related]  

  • 11. Harmonisation in pharmacovigilance.
    Edwards IR; Biriell C
    Drug Saf; 1994 Feb; 10(2):93-102. PubMed ID: 8011183
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacovigilance in the pharmaceutical industry.
    Talbot JC; Nilsson BS
    Br J Clin Pharmacol; 1998 May; 45(5):427-31. PubMed ID: 9643613
    [No Abstract]   [Full Text] [Related]  

  • 13. Promoting spontaneous adverse drug reaction reporting in hospitals using a hyperlink to the online reporting form: an ecological study in Portugal.
    Ribeiro-Vaz I; Santos C; da Costa-Pereira A; Cruz-Correia R
    Drug Saf; 2012 May; 35(5):387-94. PubMed ID: 22468615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 15. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacovigilance in India: Present Scenario and Future Challenges.
    Kalaiselvan V; Srivastava S; Singh A; Gupta SK
    Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives.
    Sultana J; Moretti U; Addis A; Caduff P; Capuano A; Kant A; Laporte JR; Lindquist M; Raine J; Sartori D; Trifirò G; Tuccori M; Venegoni M; van Puijenbroek E; Leone R
    Drug Saf; 2019 May; 42(5):683-687. PubMed ID: 30565019
    [No Abstract]   [Full Text] [Related]  

  • 18. Communication of findings in pharmacovigilance: use of the term "signal" and the need for precision in its use.
    Hauben M; Reich L
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):479-80. PubMed ID: 15991039
    [No Abstract]   [Full Text] [Related]  

  • 19. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.